Clinical Trials
9 trialsNCT03737734 2026-04-06
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Phase NA Active not recruiting
NCT03886181 2025-12-08
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Phase NA Terminated
NCT03889899 2025-12-02
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT04540588 2025-12-02
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
Alpha Tau Medical LTD.
Phase NA Completed
NCT04534127 2025-02-07
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT03239834 2021-08-12
Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
Vigilant Biosciences, Inc.
Completed
NCT00050388 2008-06-24
Phase II Trial of Allovectin-7® for Head and Neck Cancer
Vical
Phase 3 Completed